Publications by authors named "Simone Detre"

Claim this Profile
C
Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015).
Judith M Bliss, Holly Tovey, Abigail Evans, Chris Holcombe, Kieran Horgan, Simone Detre

Breast Cancer Res· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study.
Elena Lopez-Knowles, Simone Detre, Margaret Hills, Eugene F Schuster, Maggie C U Cheang

Breast Cancer Res· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer.
Kimberly J Cocce, Jeff S Jasper, Taylor K Desautels, Logan Everett, Suzanne Wardell, Simone Detre

Cell Rep· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the Spatial Heterogeneity of Breast Cancers: Associations Between Computed Tomography and Immunohistochemistry.
David K Woolf, Sonia P Li, Simone Detre, Alison Liu, Andrew Gogbashian

Biomark Cancer· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy.
Tengfei Xiao, Wei Li, Xiaoqing Wang, Han Xu, Jixin Yang, Simone Detre

Proc Natl Acad Sci U S A· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Embryonic transcription factor SOX9 drives breast cancer endocrine resistance.
Rinath Jeselsohn, MacIntosh Cornwell, Matthew Pun, Gilles Buchwalter, Mai Nguyen, Simone Detre

Proc Natl Acad Sci U S A· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials.
Jack Cuzick, Adam R Brentnall, Corrinne Segal, Helen Byers, Caroline Reuter, Simone Detre

J Clin Oncol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial.
Simone I Detre, Susan Ashley, Kabir Mohammed, Ian E Smith, Trevor J Powles

Cancer Prev Res (Phila)· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials.
Adam R Brentnall, Jack Cuzick, Helen Byers, Corrinne Segal, Caroline Reuter, Simone Detre

Breast Cancer Res Treat· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas.
Elena López-Knowles, Qiong Gao, Maggie Chon U Cheang, James Morden, Joel Parker, Simone Detre

Breast Cancer Res· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039).
Alexandra Leary, Abigail Evans, Stephen R D Johnston, Roger A'Hern, Judith M Bliss, Simone Detre

Clin Cancer Res· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer.
Isabel F Pinhel, Fiona A Macneill, Margaret J Hills, Janine Salter, Simone Detre

Breast Cancer Res· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer.
Zara Ghazoui, Francesca M Buffa, Anita K Dunbier, Helen Anderson, Tim Dexter, Simone Detre

Clin Cancer Res· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative validation of the SP6 antibody to Ki67 in breast cancer.
Lila Zabaglo, Janine Salter, Helen Anderson, Emma Quinn, Margaret Hills, Simone Detre

J Clin Pathol· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo.
Susana Banerjee, Roger A'Hern, Simone Detre, Amanda J Littlewood-Evans, Dean B Evans

Clin Cancer Res· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.
Alexandra F Leary, Suzanne Drury, Simone Detre, Sunil Pancholi, Anne E Lykkesfeldt

Clin Cancer Res· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.
Ian E Smith, Geraldine Walsh, Anthony Skene, Antonio Llombart, José Ignacio Mayordomo, Simone Detre

J Clin Oncol· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo.
Lesley-Ann Martin, Julia E Head, Sunil Pancholi, Janine Salter, Emma Quinn, Simone Detre

Mol Cancer Ther· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
Mitch Dowsett, Ian E Smith, Stephen R Ebbs, J Michael Dixon, Anthony Skene, Simone Detre

J Natl Cancer Inst· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.
Russell Burcombe, George D Wilson, Mitch Dowsett, Ifty Khan, Paul I Richman, Simone Detre

Breast Cancer Res· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer.
Mitch Dowsett, Ian E Smith, Steve R Ebbs, J Michael Dixon, Anthony Skene, Simone Detre

Clin Cancer Res· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.
M Carolina Gutierrez, Simone Detre, Stephen Johnston, Syed K Mohsin, Jiang Shou

J Clin Oncol· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
Mitch Dowsett, Steve R Ebbs, J Michael Dixon, Anthony Skene, Clive Griffith, Simone Detre

J Clin Oncol· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Mitch Dowsett, Ian E Smith, Steve R Ebbs, J Michael Dixon, Anthony Skene, Simone Detre

Clin Cancer Res· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model.
Simone Detre, Sharon Riddler, Janine Salter, Roger A'Hern, Mitch Dowsett

Cancer Res· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis